
Aetna announced it they would no longer be requiring prior approval for cataract surgeries starting in July.

Aetna announced it they would no longer be requiring prior approval for cataract surgeries starting in July.

Investigators from Toronto compared morbidity and mortality outcomes among patients with acute decompensated heart failure (ADHF) before and during the COVID-19 pandemic.

Health insurers and self-insured employers must post prices they have negotiated with providers; Senate Democrats draft a plan to let Medicare negotiate prices with manufacturers before midterm elections; vaccines receiving tweaking in the fall will need to cover Omicron variants.

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

Of 10 patient-reported outcome measures studied, only 2 received an ‘A’ rating for sufficient content validity and internal structure.

Advanced practitioners (APs) have a role to play in strategies for integrating biosimilars into clinical practice.

In the second of 2 parts, Nathan H. Walcker, MBA, CEO of Florida Cancer Specialists & Research Institute (FCS), discusses what he’d like value-based care to look like going forward. CMS ended the Oncology Care Model (OCM) yesterday after 6 years and has invited practices to apply for a successor model, the Enhancing Oncology Model.

Panelists of a keynote session at AHIP 2022 discuss how lessons learned from investment and infrastructure in public health during the COVID-19 pandemic can be leveraged to promote equitable care for all Americans and prepare for the next public health emergency.

Patients with iCCA, particularly those whose disease progresses following first-line chemotherapy, have limited overall treatment options. Data presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting show that patients may soon have a new agent to fight this rare cancer in futibatinib (Taiho Oncology), an FGFR inhibitor.

Will Nutland, DrPH, is cofounder of PrEPster, honorary assistant professor at the London School of Hygiene and Tropical Medicine, and an activist.

Elli Papaemmanuil, PhD, assistant professor in computational oncology, Memorial Sloan Kettering Cancer Center, discussed current knowledge on the molecular profile of myelodysplastic syndromes (MDS) and potential use of precision medicine.

Viral Shah, MD, an endocrinologist and scientist, discusses the growing field of research into the connections between type 1 diabetes (T1D) and osteoporosis.

In the first of 2 parts, Nathan H. Walcker, MBA, CEO of Florida Cancer Specialists & Research Institute (FCS), discusses the future of value-based care for the practice as the Oncology Care Model comes to an end today. This week, CMS announced it will launch a successor model.

Outcomes for patients with ankylosing spondylitis (AS) and psoriatic arthritis (PsA) may depend on gender, time to diagnosis, and body mass index (BMI), according to subanalyses of the AQUILA study of patients taking secukinumab.

Jonathan Kentley, MBBS, MSc, research fellow at Memorial Sloan Kettering Cancer Center, talks about how dermatologists are working with artificial intelligence (AI) while still making sure patient voices are heard.

Senators did not approve the 9-nominee commission to reshape the Veteran Affairs health care system; US population is getting older and more diverse; HHS issued guidance to protect patient privacy related to sexual and reproductive care.

Patients from this diverse cohort experienced improvements in atopic dermatitis (AD) clinical scores after a year or more of treatment with dupilumab.

A recent study found that pulmonary rehabilitation after hospitalization for chronic obstructive pulmonary disease (COPD) resulted in a net cost savings.

The Diabetes-Specific Risk-Taking Inventory proved useful in assessing risk-taking behavior in adolescents with type 1 diabetes (T1D), but future research on potential interventions is needed.

In patients with BRAF-mutated non–small-cell lung cancer (NSCLC), further research is needed to identify more treatment options that address the scope of subsets in this population.

Extended safety and effectiveness of the Omnipod 5 AID system were investigated in this 12-month extension of a previous 3-month study conducted among persons living with type 1 diabetes (T1D).

At the end of September 2021, Freda Pyles, a resident of rural Pennsylvania, began an antibiotic for a dental infection. That set off a 6-month battle with Clostridioides difficile, which was misdiagnosed a few times before she was treated at Yale-New Haven Hospital. Here, she describes how she contracted the infection and what happened afterwards.

Despite current guidelines recommending combination therapy, there are certain patients with pulmonary arterial hypertension (PAH) who remain on monotherapy for specific reasons.

Medicare Advantage (MA) plans are denying care while overcharging the government, watchdogs said at a Congressional hearing; overturn of Roe v Wade will not change how military treatment facilities provide abortions; the CDC activates the Emergency Operations Center in response to monkeypox.

The utility of value-based frameworks for payers, providers, and those involved in kidney care delivery was addressed during a session at AHIP 2022.

Research presented at the 2022 American Society of Clinical Oncology Annual Meeting shows White patients with myelodysplastic syndrome (MDS) have worse overall survival outcomes than African American patients, contrary to previous findings in other cancer types.

The researchers of this new study wrote that although SMA carrier screening is recommended for all couples, current testing methods primarily focus on copy number loss of SMN1, which can result in false-negative test results due to intragenic mutations and silent carriers falling under the radar.

The tool relies on factors including creatinine, anti–double-stranded DNA antibody, and gender, among others.

Creating and validating effective risk assessment models could help facilitate appropriate prophylaxis for hemophilia, but more research is needed to confirm the prognostic value of various clinical risk factors and biomarkers.

A real-world analysis found that comprehensive genomic profiling (CGP) in patients with non–small cell lung cancer (NSCLC) increases their therapy options patients and CGP testing needs to be utilized more.

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512
© 2025 MJH Life Sciences®
All rights reserved.
